Skip to main content
. 2019 Sep 23;129(11):4593–4608. doi: 10.1172/JCI120879

Figure 3. Upregulation of ANGPTL4 in patients with DME.

Figure 3

(A and B) Levels of ANGPTL4 in aqueous samples from nondiabetic (control) patients and diabetic patients with DME who have not previously received anti-VEGF therapy or have not received anti-VEGF therapy for 12 weeks or longer in the sample eye (see Supplemental Table 2) (A) and its correlation with EC permeability. r = –0.8; P < 0.0001 (B). (C and D) ANGPTL4 (C) and VEGF (D) protein levels in DME patients without previous treatment with anti-VEGF therapy (DME Untx) or DME patients who have received a single treatment with anti-VEGF therapy in the sample eye within 6 weeks of sample collection (DME Tx) compared with nondiabetic (control) patients. Mann-Whitney U test (A), Pearson correlation (B), or 1-way ANOVA (C and D). *P < 0.05; **P < 0.01; ****P < 0.0001.